Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...

The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Princeton, N.J.-based Bristol Myers BMY had net income of $1.2 billion, or 60 cents a share, in the quarter, down from $1.9 ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...

BofA raised the firm’s price target on Bristol Myers (BMY) to $60 from $55 and keeps a Neutral rating on the shares. Bristol reported ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, ...

Expectations for Bristol Myers Squibb's Q3 results have significantly declined. Despite this, check out why I maintain a "Buy ...

Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...